Skip to main content
SpringerLink
Log in

Is there a role for vindesine in the treatment of non-small cell lung cancer?

  • Review
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Vindesine is a semisynthetic derivative of vinblastine which has been evaluated in clinical studies since the late 1970's. The literature on vindesine in the treatment of non-small cell lung cancer has been reviewed and all aspects of vindesine treatment in this disease has been covered. It is concluded that vindesine as a single agent yields a response rate of 18% based on the treatment of 295 patients included in phase II trials (95% confidence limits 13%–22%). No difference was observed among the three major histologic types of non-small cell lung cancer. In phase III trials, the response rate and confidence limits are at a similar level. Combination chemotherapy including vindesine plus cisplatin ranks among the most active treatments in non-small cell lung cancer and is as active as etoposide plus cisplatin, both with respect to response rate and survival. It has not been documented that the addition of one or two other drugs to the combination of vindesine yields an increase in survival. When best supportive care was compared with a combination of vindesine plus cisplatin, the group with chemotherapy was attributed a survival advantage in all three studies published, and the difference was statistically significant in two of these three studies. Thus, vindesine has a well documented activity in non-small cell lung cancer and ranks among the most active single agents in this disease. Vindesine is also part of several active combination chemotherapies among which the combination of vindesine plus cisplatin is particularly interesting, because it has been repeatedly shown to prolong survival as compared to supportive care. Especially this latter point leads to the conclusion that there is a role for vindesine in the treatment of non-small cell lung cancer. However, the concept of chemotherapy in this disease remains investigational even though the advances seen in recent years clearly merit further studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Sørensen JB, Hansen, HH: Review of methodological problems in the interpretation of phase II trials in non-small cell lung cancer. In: Arriagada R (ed) Treatment Modalities in Lung Cancer. Antibot Chemother. asel: Karger 41:57–64, 1988

    Google Scholar 

  2. Sørensen JB, Badsberg JH, Hansen HH: Response to cytostatic treatment in inoperable adenocarcinoma of the lung: critical implications. Br J Cancer 60: 389–393, 1989

    Google Scholar 

  3. Ruckdeschel JC, Finkelstein DM, Ettinger DS, Creech RH, Mason BA, Joss RA, Vogl S: A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 4:14–22, 1986

    Google Scholar 

  4. Eagan RT, Ingle JN, Frytak S: Platinum-based polychemotherapy versus dianhydrogalactitol in advanced non-small cell lung cancer. Cancer Treat Rep 61:1339–1345, 1977

    Google Scholar 

  5. Warr D, McKinney S, Tannock I: Influence of measurement error on assessment of response to anticancer chemotherapy: proposal for new criteria of tumor response. J Clin Oncol 2: 1040, 1984

    Google Scholar 

  6. Rapp E, Pater JL, Willan A, Cormier Y, Murray N, Evans WK, Hodson DI, Clark DA, Feld R, Arnold AM, Ayoub JI, Wilson KS, Latreille J, Wierzbicki RF, Hill DP: Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer — report of a Canadian multicenter randomized trial. J Clin Oncol 6:633–641, 1988

    Google Scholar 

  7. Quiox É, Dietemann A, Charbonneau J, Boutin C, Meurice C, Orlando JP, Ducolone A, Pauli G, Roegel É: La chimiothérapie comportant du cisplatine est-elle utile dans le cancer bronchique non microcellulaire au stade IV? Résultats d'une étude randomisée. Bull Cancer 78:341–346, 1991

    Google Scholar 

  8. Feld R: Quality of life in patients with non-small cell lung cancer treated with chemotherapy: Eur J Cancer Clin Oncol 23:357–359, 1987

    Google Scholar 

  9. Hopwood P, Thatcher N: Preliminary experience with quality of life evaluation in patients with lung cancer. Oncology 4:158–162, 1990

    Google Scholar 

  10. Ganz PA, Haskell CM, Figlin RA, La Soto N, Siau J for the UCLA Solid Tumor Study Group: Estimating the quality of life in a clinical trial of patients with metastatic lung cancer using the Karnofsky performance status and the functional living index — cancer. Cancer 61:849–856, 1988

    Google Scholar 

  11. Osoba D, Rusthoven JJ, Turnbull KA, Evans WK, Shepherd FA: Combination chemotherapy with bleomycin, etoposide and cisplatin in metastatic non-small cell lung cancer. J Clin Oncol 3:1478, 1985

    Google Scholar 

  12. Burke MT, Gralla R, Kris M, Howard J, Berenson S, Monras P: The palliative influence of response to chemotherapyin patients with stage III non-small cell lung cancer(NSCLC). Proc Am Soc Clin Oncol 5:185, 1985

    Google Scholar 

  13. Fernandez C, Rosell R, Abad-Esteve A, Monras P, Moreno I, Serichol M, Roviralta M: Quality of life during chemotherapy in non-small cell lung cancer patients. Acta Oncologica 28:29–33, 1989

    Google Scholar 

  14. Bakker W, Van Oosterom AT, Aaronson NK, nVan Breukelen FJM, Bins MC, Hermans J: Vindesine, cisplatin, and bleomycin combination chemotherapy in non-small cell lung cancer: survival and quality of life. Eur J Cancer Clin Oncol 22:963–970, 1986

    Google Scholar 

  15. Dyke RW, Nelson RL: Phase I anti-cancer agents. Vindesine (desacetyl vinblastine amide sulfate). Cancer Treat Rev 4:135–142, 1977

    Google Scholar 

  16. Currie VE, Wong P, Krakoff IH, Young CW: Phase I trial of vindesine in patients with advanced cancer. Cancer Treat Rep 62:1333–1336, 1978

    Google Scholar 

  17. Coldberg ID, Bloomer WD, Dawson DM: Nervous system toxic effects of cancer therapy. JAMA 247:1437–1441, 1982

    Google Scholar 

  18. Bayssas M, Gouveia J, de Vassal F, Misset J-L, Schwarzenberg L, Ribaud P, Musset M, Jasmin C, Hayat M, Mathé G: Vindesine: a new vinca alkaloid. Recent Results Cancer Res 74:91–97, 1980

    Google Scholar 

  19. Gralla RJ, Raphael RB, Golbey RB, Young CW: Phase II evaluation of vindesine in patients with non-small cell carcinoma of the lung. Cancer Treat Rep 63:1343, 1979

    Google Scholar 

  20. Mattson K, Holsti LR, Salmo M, Saastamoinen M, Ahlstedt S, Holsti P: Vindesine in the treatment of bronchogenic carcinoma: preliminary results of two clinical trials. In: Current Chemotherapy and Infectious Disease. Proceedings, 11 ICC and 19 ICAAC, Boston, 1981: 1569

  21. Østerlind K, Hørbov S, Dombernowsky P, Rørth M, Hansen HH: Vindesine in the treatment of squamous cell carcinoma, adenocarcinoma, and large cell carcinoma of the lung. Cancer Treat Rep 66:305, 1982

    Google Scholar 

  22. Luedke SL, Luedke DW, Petruska P, Broun GO, Reed G, Leavitt J: Vindesine (VDS) monochemotherapy for non-small cell lung cancer: a report of 45 cases. Cancer Treat Rep 66:1409, 1982

    Google Scholar 

  23. Furnas BE, Williams SD, Einhorn LH, Cobleigh MA: Vindesine: an effective agent in the treatment of non-small cell lung cancer. Cancer Treat Rep 66:709, 1982

    Google Scholar 

  24. Vogelzang NJ, Peterson BA, Kennedy BJ, Vosika GJ, Conroy JA: Vindesine in bronchogenic carcinoma. A phase II trial. Am J Clin Oncol 5:41, 1982

    Google Scholar 

  25. Hutcheon AW, Palmer JBD, Pratt MA, Clark RA: Phase II evaluation of vindesine in non-small cell bronchogenic carcinoma. Cancer Treat Rep 67:1041, 1983

    Google Scholar 

  26. Sledge GW, Clark GM, Von Hoff DD: Phase II trial of vindesine in adenocarcinoma of the lung. Cancer Treat Rep 68:557, 1984

    Google Scholar 

  27. Fujita J, Saijo N, Eguchi K, Shinkai T, Tominaga K, Sasaki Yet al: Phase II study of vindesine in patients with non-small cell lung cancer. Jpn J Cancer Res 7–6:902, 1985

    Google Scholar 

  28. Sørensen JB, Hansen HH, Dombernowsky P, Bork E, Malmberg R, Aabo K, Bødker B, Hansen M: Chemotherapy for adenocarcinoma of the lung (WHO III): a randomized study of vindesine versus lomustine, cyclophosphamide, and methotrexate versus all four drugs. J Clin Oncol 5:1169–1177, 1987

    Google Scholar 

  29. Luedke DW, Einhorn L, Omura GA, Ravi Sarma P, Bartolucci AA, Birch R, Greco FA: Randomized comparison of two combination regimens versus minimal chemotherapy in non-small cell lung cancer: A Southeastern Cancer Study Group trial. J Clin Oncol 8:886–891, 1990

    Google Scholar 

  30. Einhorn LH, Loehrer PJ, Williams SD, Meyers S, Gabrys T, Nattan SR, Woodburn R, Drasga R, Songer J, Fisher W, Stephens D, Hui S: Random prospective study of vindesine versus vindesine plus high-dose cisplatin versus vindesine plus cisplatin plus mitomycin-C in advanced non-small cell lung cancer. J Clin Oncol 4:1037–1043, 1986

    Google Scholar 

  31. Elliott JA, Ahmedzai S, Hole D, Dorward AJ, Stevenson RD, Kaye SB, Banham SW, Stack BHR, Calman KC: Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 20:1025–1032, 1984

    Google Scholar 

  32. Popkin JD, Hong WK, Cersosimo RJ, Faling LJ, Snow MN, Fofonoff SA: A prospective randomized trial of combination vindesine and cisplatin versus single-agent vindesine in advanced non-small cell lung cancer. Pharmacotherapy 5:20–2, 1985

    Google Scholar 

  33. Luedke DW, Luedke SL, Petruska P, Broun GO, Leavitt J, Leuter J: A randomized prospective study of vindesine versus doxorubicin and cyclophosphamide in the treatment of epidermoid lung cancer. Cancer 51:778–82, 1983

    Google Scholar 

  34. Jewkes J, Harper PG, Tobias JS, Geddes DM, Souhami RL, Iro SG: Comparison of vincristine and vindesine in the treatment of inoperable non-small cell bronchial carcinoma. Cancer Treat Rep 67:1119–1121, 1983

    Google Scholar 

  35. Gatzemeier U, Cavalli F, Häussinger K, Kaukel E, Koschel G, Martinelli Get al: Phase III trial with and without lonidamine in non-small cell lung cancer. Semin Oncol 18:42–48, 1991

    Google Scholar 

  36. Kris MG, Gralla RJ, Kalman LA, Kelsen DP, Casper ES, Burke MT, Groshen S, Cibas IR, Bagin R, Heelan RT: Randomized trial comparing vindesine plus cisplatin with vinblastine plus cisplatin in patients with non-small cell lung cancer, with an analysis of methods of response assessment. Cancer Treat Rep 69:387–395, 1985

    Google Scholar 

  37. Paccagnella A, Brandes A, Pappagallo GL, Simioni G, Fosser VP, Vinante O, Salvagno L, De Besi P, Sileni VC, Fornasiero A, Fiorentino MV: Cisplatin plus vindesine versus cisplatin plus VP-16 versus doxorubicin plus cytoxan in non-small cell carcinoma of the lung. A randomized study. Tumori 72:417–425, 1986

    Google Scholar 

  38. Dhingra HM, Valdivieso M, Carr DT, Chiuten DF, Farha P, Murphy WK, Spitzer G, Umsawasdi T: Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small cell lung cancer. J Clin Oncol 3:176–183, 1985

    Google Scholar 

  39. Hainsworth JD, Johnson DH, Hande KR, Greco FA: Chemotherapy of advanced non-small cell lung cancer: A randomized trial of threecis-platin-based chemotherapy regimens. Am J Clin Oncol 12:345–349, 1989

    Google Scholar 

  40. Hansen HH, Selawry OS, Simon Ret al: Combination chemotherapy of advanced lung cancer. Cancer 38: 2201–2207, 1976

    Google Scholar 

  41. Kawahara M, Furuse K, Kodama N, Yamamoto M, Kubota K, Takada M, Negoro S, Kusunoki Y, Matui K, Takifuji N, Fukuoka M: A randomized study of cisplatin versus cisplatin plus vindesine for non-small cell lung carcinoma. Cancer 68:714–719, 1991

    Google Scholar 

  42. Gralla RJ, Casper ES, Kelsen DP, Braun DW, Dukeman ME, Martini N, Young CW, Golbey RB: Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95:414–420, 1981

    Google Scholar 

  43. Nagao K, Fujisawa T, Miyamota T, Kikuchi N, Takizawa H, Satoh K, Yamagishi F, Yamagushi T, Mizutani F, Nakano K, Fuchigami T, Arita M, Kohno N, Ohshima H, Yoshida A, Baba M, Ooiwa K, Kawano Y, Kunitomo F, Mamoto T, Kuriyama T, Yamaguchi Y: Comparative study on vindesine plus cisplatin treatment for advanced non-small cell lung cancer — three divided doses (35 mg/m2, day 1,8,15) and single dose (80 mg/m2, day 1) of cisplatin. Jpn J Cancer Chemother 18:425–430, 1991

    Google Scholar 

  44. Shinkai T, Saijo N, Egushi K, Sasaki Y, Tominaga K, Akurai M, Suga J, Miyaoka H, Sano T, Keicho N, Takahashi H, Ishihara J, Tamura T, Hoshi A, Jett JR: Cisplatin and vindesine combination chemotherapy for non-small cell lung cancer: A randomized trial comparing two dosages of cisplatin. Jpn J Cancer Res 77:782–789, 1986

    Google Scholar 

  45. Briancon S, Lamaza R, Barral D, Feintrenie X, Thisse JY, Ermann J, Lamy P: Vindesine et chimiothérapie des cancers bronchiques non microcellulaires au stade III. Essai randomisé en bithérapie — cyclophosphamide vs cisplatinum. Pneumologie 22:639–643, 1983

    Google Scholar 

  46. Gatzemeier U, Heckmayr M, Hossfeld DK, Kaukel E, Koschel G, Neuhauss R: A randomized trial with mitomycin-C/ifosfamide versus mitomycin-C/vindesine versus cisplatin/etoposide in advanced non-small cell lung cancer. Am J Clin Oncol 14:405–411, 1991

    Google Scholar 

  47. Shinkai T, Saijo N, Tominaga K, Eguchi K, Shimizu E, Sasaki Y, Fujita J, Futami H: Comparison of vindesine plus cisplatin or vindesine plus mitomycin in the treatment of advanced non-small cell lung cancer. Cancer Treat Rep 69: 945–951, 1985

    Google Scholar 

  48. Shinkai T, Egushi K, Sasaki T, Tamura T, Ohe Y, Kojima A, Oshita F, Saijo N: A randomised clinical trial of vindesine plus cisplatin versus mitomycin plus vindesine and cisplatin in advanced non-small cell lung cancer. Eur J Cancer 27:571–575, 1991

    Google Scholar 

  49. Fukuoka M, Masuda N, Furuse K, Negoro S, Takada M, Matsui K, Takifuji N, Kudoh S, Kawahara M, Ogawara M, Kodama N, Kubota K, Yamamoto M, Kusunoki Y: A randomized trial in inoperable non-small cell lung cancer: vindesine and cisplatin versus mitomycin, vindesine, and cisplatin versus etoposide and cisplatin alternating with vindesine and mitomycin. J Clin Oncol 9:606–613, 1991

    Google Scholar 

  50. Rosell R, Abad-Esteve A, Moreno I, Barnadas A, Carles J, Rnandez C, Ribelles N, Culubret M: A randomized study of two vindesine plus cisplatin-containing regimen with the addition of mitomycin C or ifosfamide in patients with advanced non-small cell lung cancer. Cancer 65:1692–1699, 1990

    Google Scholar 

  51. Harvey VJ, Slevin ML, Cheek SP, Barnell MJ, Gregory W, Hompson JPS, Wrigley PFM: A randomized trial comparing vindesine and cisplatinum to vindesine and methotrexate in advanced non-small cell lung carcinoma. Eur J Cancer Clin Oncol 23:1615–1619, 1987

    Google Scholar 

  52. Kelsen D, Gralla R, Stoopler M, Casper E, Cheng E, Kosloff C, Golbey R: Cisplatin, doxorubicin, cyclophosphamide and vindesine combination chemotherapy for non-small cell lung cancer. Cancer Treat Rep 66:247–251, 1982

    Google Scholar 

  53. Cellerino R, Tummarello D, Piga A: Chemotherapy or not in advanced non-small cell lung cancer? Lung Cancer 6:99–109, 1990

    Google Scholar 

  54. Woods RL, Williams CJ, Levi J, Page J, Bell D, Byrne M, Kerestes ZL: A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. Br J Cancer 61:608–611, 1990

    Google Scholar 

  55. Williams CJ, Woods R, Levi J, Page J: Chemotherapy for non-small cell lung cancer: a randomized trial of cisplatin/vindesine ν no chemotherapy. Semin Oncol 15, suppl 5:58–61, 1988

    Google Scholar 

  56. Mountain CF: A new international staging system for lung cancer. Chest 89 Suppl 4:225–233, 1986

    Google Scholar 

  57. Mountain CF: The biological operability of stage III non-small cell lung cancer. Ann Thorac Surg 40:60–64, 1985

    Google Scholar 

  58. Murren JR, Buzaid AC, Hait WN: Pulmonary perspective. Critical analysis of neoadjuvant therapy for state IIIa non-small cell lung cancer: Am Rev Respir Dis 143:889–894, 1991

    Google Scholar 

  59. Bitran JD, Golomb HM, Hoffman PC, Albain K, Evans R, Little AG, Purl S, Skosey C: Protochemotherapy in non-small cell lung carcinoma. An attempt to increase surgical resectability and survival. A preliminary report. Cancer 57:44–53, 1986

    Google Scholar 

  60. Vokes EE, Bitran JD, Hoffman PC, Ferguson MK, Weichselbaum RR, Golomb HM: Neoadjuvant vindesine, etoposide, and cisplatin for locally advanced non-small cell lung cancer. Final report of a phase 2 study. Chest 96:110–113, 1989

    Google Scholar 

  61. Martini N, Kris MG, Gralla RJ, Bains MS, McCormack PM, Kaiser LR, Burt ME, Zaman MB: The effects of preoperative chemotherapy on the resectability of non-small cell lung carcinoma with mediastinal lymph node metastases (N2 M0). Ann Thorac Surg 45:370–379, 1988

    Google Scholar 

  62. Spain RC: Neoadjuvant mitomycin C, cisplatin and infusion vinblastine in locally and regionally advanced non-small cell lung cancer: problems and progress from the perspective of long-term follow-up. Semin Oncol 15 Suppl 4:6–15, 1988

    Google Scholar 

  63. Sridhar KS, Thurer RJ, Savaray N, Benedetto P, Feun L, Altman S, Schwade J: Pre and postoperative (OP) adjuvant chemotherapy (CT) in locally advanced non-small cell lung carcinoma (NSCLC) (abstract). Proc Am Soc Clin Oncol 8:237, 1989

    Google Scholar 

  64. Raut Y, Huu N, Clavier J, Guillerm D, Barra JA: Surgery and chemotherapy. A new method of treatment for squamous cell bronchial carcinoma. J Thorac Cardiovasc Surg 88: 754–757, 1984

    Google Scholar 

  65. Marangolo M, Fiorentini G: Adjuvant chemotherapy of non-small cell lung cancer: A review. Semin Oncol 15, Suppl 7:13–17, 1988

    Google Scholar 

  66. Holmes EC, Gail M and The Lung Cancer Study Group: Surgical adjuvant therapy for stage II and stage III adenocarcinoma and large-cell undifferentiated carcinoma. J Clin Oncol 4:710–715, 1986

    Google Scholar 

  67. Ayoub J, Duranceau A, Lorange G, Robidoux A, Page A, Joassin A: Effectiveness of adjuvant chemotherapy in operable non-small cell lung cancer. Proc Am Soc Clin Oncol 5:187, 1986

    Google Scholar 

  68. Le Chevalier T, Arriagada R, Baldeyrou P, Martin M, Duroux P, Jacquotte A, Cancho-Garnier H, Rouesse Y: Combined chemotherapy (vindesine, lomustine, cisplatin, and cyclophosphamide) and radical radiotherapy in inoperable nonmetastatic squamous cell carcinoma of the lung. Cancer Treat Rep 69:469–72, 1985

    Google Scholar 

  69. Watkin SW, Errington RD, Green JA, Warenius HM: Sequential combination chemotherapy and radiotherapy in locally advanced non-small cell carcinoma of the bronchus. Respir Med 83:227–31, 1989

    Google Scholar 

  70. Wolf M, Havemann K, Stalleicken D, Gropp C, Massberg M, Hans K, von Bültzingslöwen F, Klasen H, Becker H, Schroeder M, Hruskai E, Hirschmann H, Gerdes H, Hässler R, Mendes S, Pieritz HG, Braun C, Holle R: Ergebnisse zweier multizentrischer therapiestudien beim inoperablen nichtkleinzelligen bronchialkarzinom. Onkologie 11:222–31, 1988

    Google Scholar 

  71. Karstens JH, Andreopoulos D, Ammon J: Initial tumor size and local control in stage III non-small cell lung cancer treated by radio-chemotherapy. Onkologie 13:144–145, 1990

    Google Scholar 

  72. Johnson DH, Einhorn LH, Bartolucci A, Birch R, Omura G, Perez CA, Greco FA: Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 113: 33–38, 1990

    Google Scholar 

  73. Niitamo-Korhonen S, Holsti P, Holsti LR, Pyrhönen S, Mattson K: A comparison ofcis-platinum-vindesine and cisplatinum-etoposide combined with radiotherapy for previously untreated localized inoperable non-small cell lung cancer. Eur J Cancer Clin Oncol 25:1039–1043, 1989

    Google Scholar 

  74. Van Houtte P, Klastersky J, Renaud A: Induction chemotherapy with cisplatin, etoposide, and vindesine before radiation therapy for non-small cell lung cancer. In: Arriagada R (ed) Treatment Modalities in Lung Cancer. Antibiot Chemother, Basel: Karger, 41:131–137, 1988

    Google Scholar 

  75. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Tarayre Met al: Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small cell lung cancer: First analysis of a randomized trial in 353 patients. J Natl Cancer Inst 83:417–423, 1991

    Google Scholar 

  76. Le Chevalier T, Arriagada R, Tarayre M, Lacombe-Terrier M-J, Laplanche A, Quoix E, Ruffie P, Martin M, Douillard J-Y: Significant effect of adjuvant chemotherapy on survival in locally advanced non-small cell lung carcinoma. J Nat Cancer Inst 84:58, 1992

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Rigshospitalet, Copenhagen, Denmark

    Jens Benn Sørensen & Heine H. Hansen

Authors
  1. Jens Benn Sørensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Heine H. Hansen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sørensen, J.B., Hansen, H.H. Is there a role for vindesine in the treatment of non-small cell lung cancer?. Invest New Drugs 11, 103–133 (1993). https://doi.org/10.1007/BF00874146

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00874146

Key words

Search

Navigation